Literature DB >> 23109108

Transsynaptic inhibition of spinal transmission by A2 botulinum toxin.

Norio Akaike1, Min-Chul Shin, Masahito Wakita, Yasushi Torii, Tetsuhiro Harakawa, Akihiro Ginnaga, Keiko Kato, Ryuji Kaji, Shunji Kozaki.   

Abstract

Type A botulinum toxin blocks not only ACh release from motor nerve terminals but also central synaptic transmission, including glutamate, noradrenaline, dopamine, ATP, GABA and glycine. Neurotoxins (NTXs) are transported by both antero- and retrogradely along either motor or sensory axons for bidirectional delivery between peripheral tissues or the CNS. A newly developed type A2 NTX (A2NTX) injected into one rat foreleg muscle was transported to the contralateral muscle. This finding was consistent with the NTX traveling retrogradely via spinal neurons and then transsynaptically through motor neurons to the contralateral motor neurons within the spinal cord and on to the soleus muscle. In the present study we found that toxin injection into the rat left soleus muscle clearly induced bilateral muscle relaxation in a dose-dependent fashion, although the contralateral muscle relaxation followed the complete inhibition of toxin-injected ipsilateral muscles. The toxin-injected ipsilateral muscle relaxation was faster and stronger in A2NTX-treated rats than A1LL (BOTOX). A1LL was transported almost equally to the contralateral muscle via neural pathways and the bloodstream. In contrast, A2NTX was mainly transported to contralateral muscles via the blood. A1LL was more successfully transported to contralateral spinal neurons than A2NTX. We also demonstrated that A1LL and A2NTX were carried from peripheral to CNS and vice versa by dual antero- and retrograde axonal transport through either motor or sensory neurons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23109108      PMCID: PMC3591713          DOI: 10.1113/jphysiol.2012.242131

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  26 in total

Review 1.  Botulinum toxin type B.

Authors:  Neil S Sadick
Journal:  Dermatol Surg       Date:  2003-04       Impact factor: 3.398

Review 2.  Techniques: applications of the nerve-bouton preparation in neuropharmacology.

Authors:  Norio Akaike; Andrew J Moorhouse
Journal:  Trends Pharmacol Sci       Date:  2003-01       Impact factor: 14.819

Review 3.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

4.  Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses.

Authors:  Norio Akaike; Yushi Ito; Min-Chul Shin; Kiku Nonaka; Yasushi Torii; Tetsuhiro Harakawa; Akihiro Ginnaga; Shunji Kozaki; Ryuji Kaji
Journal:  Toxicon       Date:  2010-07-30       Impact factor: 3.033

5.  A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4.

Authors:  Joseph W Arndt; Mark J Jacobson; Enrique E Abola; Charles M Forsyth; William H Tepp; James D Marks; Eric A Johnson; Raymond C Stevens
Journal:  J Mol Biol       Date:  2006-07-27       Impact factor: 5.469

Review 6.  Pharmacology of therapeutic botulinum toxin preparations.

Authors:  Dirk Dressler; Reiner Benecke
Journal:  Disabil Rehabil       Date:  2007-12-15       Impact factor: 3.033

7.  Novel Clostridium botulinum toxin gene arrangement with subtype A5 and partial subtype B3 botulinum neurotoxin genes.

Authors:  Nir Dover; Jason R Barash; Stephen S Arnon
Journal:  J Clin Microbiol       Date:  2009-05-06       Impact factor: 5.948

8.  Focal stimulation of single GABAergic presynaptic boutons on the rat hippocampal neuron.

Authors:  Norio Akaike; Nobuya Murakami; Shutaro Katsurabayashi; Young-Ho Jin; Takayoshi Imazawa
Journal:  Neurosci Res       Date:  2002-03       Impact factor: 3.304

9.  Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.

Authors:  Yasushi Torii; Naotoshi Kiyota; Nakaba Sugimoto; Yuichiro Mori; Yoshitaka Goto; Tetsuhiro Harakawa; Shinji Nakahira; Ryuji Kaji; Shunji Kozaki; Akihiro Ginnaga
Journal:  Toxicon       Date:  2010-10-26       Impact factor: 3.033

10.  Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution.

Authors:  Diane D-S Tang-Liu; K Roger Aoki; J Oliver Dolly; Anton de Paiva; Tara L Houchen; Leslie F Chasseaud; Colin Webber
Journal:  Toxicon       Date:  2003-10       Impact factor: 3.033

View more
  24 in total

1.  Direct central action of intramuscularly injected botulinum toxin: is it harmful or beneficial?

Authors:  Ryuji Kaji
Journal:  J Physiol       Date:  2013-02-15       Impact factor: 5.182

2.  Multiple domains of tetanus toxin direct entry into primary neurons.

Authors:  Faith C Blum; William H Tepp; Eric A Johnson; Joseph T Barbieri
Journal:  Traffic       Date:  2014-08-11       Impact factor: 6.215

3.  Botulinum toxin B in the sensory afferent: transmitter release, spinal activation, and pain behavior.

Authors:  Marc J Marino; Tetsuji Terashima; Joanne J Steinauer; Kelly A Eddinger; Tony L Yaksh; Qinghao Xu
Journal:  Pain       Date:  2013-12-11       Impact factor: 6.961

4.  Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.

Authors:  Molly S Moritz; William H Tepp; Heather N'te Inzalaco; Eric A Johnson; Sabine Pellett
Journal:  Toxicon       Date:  2019-06-07       Impact factor: 3.033

5.  Gastrointestinal Uses of Botulinum Toxin.

Authors:  Maria Cariati; Maria Michela Chiarello; Marco Cannistra'; Maria Antonietta Lerose; Giuseppe Brisinda
Journal:  Handb Exp Pharmacol       Date:  2021

6.  In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5.

Authors:  Sabine Pellett; William H Tepp; Regina C M Whitemarsh; Marite Bradshaw; Eric A Johnson
Journal:  Toxicon       Date:  2015-06-27       Impact factor: 3.033

Review 7.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

8.  The Use of Botulinum Toxin for Treatment of the Dystonias.

Authors:  Alfredo Berardelli; Antonella Conte
Journal:  Handb Exp Pharmacol       Date:  2021

9.  Intranasal Delivery of Botulinum Neurotoxin A Protects against Hippocampal Neuron Death in the Lithium-Pilocarpine Rat Model.

Authors:  Zhi Huang; Yajun Lian; Yuan Chen; Shuang Li; Haifeng Zhang; Nanchang Xie; Yake Zheng; Shouyi Wu; Yuhan Wang; Wenchao Cheng; Qiaoman Zhang; Chengze Wang; Yinping Shi; Na Xie
Journal:  Neurochem Res       Date:  2019-03-14       Impact factor: 3.996

Review 10.  Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection.

Authors:  Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2015-06-18       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.